Trials / Recruiting
RecruitingNCT07203833
Diagnostic and Prognostic Evaluation of Vasorin During Septic Shock
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 144 (estimated)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Septic shock is the most severe form of infection. Currently, an early specific biomarker for septic shock is needed. Remember that shock situations are numerous, not only septic (eg hemorrhagic, cardiogenic...), and also accompanied by a severe pro-inflammatory state that it is sometimes difficult to distinguish from a septic state. Procalcitonin (PCT) is the most studied biomarker but still lacks sensitivity (77%) and specificity (79%). The investigators hypothesize that the Vasn could become this potential new biomarker and would allow a better diagnosis and thus the need or not to treat patients with antibiotics. The laboratory studies suggest a link between Vasn and septic shock. The goal of this project is to measure and compare plasma Vasn concentrations in 2 groups of patients = group 1: septic shock versus group 2: non-septic shock. Briefly, shock is defined as low blood pressure requiring vasopressor agents with confirmed infection (group 1) or without suspected infection such as patients admitted in intensive care unit post cardiac surgery with CBP (group 2). The investigators will also assess patient 28-day mortality to identify Vasn as a potential prognostic biomarker.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | blood sample | blood sample in order to measure the concentrations of circulating Vasn |
Timeline
- Start date
- 2025-10-19
- Primary completion
- 2027-04-01
- Completion
- 2027-05-01
- First posted
- 2025-10-02
- Last updated
- 2026-01-07
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT07203833. Inclusion in this directory is not an endorsement.